Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.0080 AUD
Change Today 0.00 / 0.00%
Volume 688.5K
PAB On Other Exchanges
Symbol
Exchange
Berlin
OTC US
As of 10:59 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

patrys ltd (PAB) Snapshot

Open
A$0.0090
Previous Close
A$0.0080
Day High
A$0.0090
Day Low
A$0.0080
52 Week High
07/8/14 - A$0.04
52 Week Low
06/12/15 - A$0.0060
Market Cap
5.6M
Average Volume 10 Days
7.8M
EPS TTM
A$-0.01
Shares Outstanding
696.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PATRYS LTD (PAB)

Related News

No related news articles were found.

patrys ltd (PAB) Related Businessweek News

No Related Businessweek News Found

patrys ltd (PAB) Details

Patrys Limited develops natural human antibody therapeutics for the treatment of cancer in Australia. The company’s clinical products include PAT-SM6, a natural human antibody used for the treatment of multiple types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers that include multiple myeloma; and PAT-SC1 for treating gastric cancer and solid tumors. It also has late stage preclinical products, such as PAT-LM1, a natural human antibody that is used in the treatment for multiple types of cancer against colon, lung, breast, ovary, and pancreatic cancers. The company was founded in 2006 and is headquartered in Melbourne, Australia.

10 Employees
Last Reported Date: 09/9/14
Founded in 2006

patrys ltd (PAB) Top Compensated Officers

Chief Operating Officer
Total Annual Compensation: A$259.5K
Compensation as of Fiscal Year 2014.

patrys ltd (PAB) Key Developments

Patrys Limited Appoints James Campbell as Managing Director and Chief Executive Officer, Effective April 13, 2015

Patrys Limited announced the appointment, effective from 13 April 2015, of Dr. James Campbell as Managing Director and Chief Executive Officer. Dr. Campbell, who was appointed as a Non-Executive Director of Patrys in November 2014, has more than 20 years of international biotechnology management and leadership experience and has been involved in the creation and/or transformation of several Australian and international biotechnology companies. Dr. Campbell will commence by leading a strategic review of the Company's operations, exploring opportunities to strengthen the company's development portfolio and focusing on investor relations. Dr. Campbell's role will initially be part-time, but is expected to progressively expand into a full-time role over the coming six months. Mr. Roger McPherson, who has been acting as Interim CEO, will provide close assistance to Dr. Campbell during this initial period in the expanded role of Chief Operating Officer. Dr. Campbell was previously the COO and CFO of ChemGenex Pharmaceuticals Limited, with responsibilities ranging from business development through to IP management and including finance and governance. More recently Dr. Campbell was actively involved in the creation, through acquisition, of Invion Limited as an executive director and remains a non-executive director of that company.

Patrys Limited Appoints James Campbell as Non-Executive Director, Effective November 12, 2014

Patrys Limited announced the appointment, effective from the close of 2014 AGM on November 12, 2014, of Dr. James Campbell as a Non-Executive Director. Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited with responsibilities ranging from IP management through to licensing and business development. More recently Dr. Campbell has guided the creation, through acquisition, of Invion Limited as an executive director and remains a non-executive director of that company, and has assisted private biotechnology companies in New Zealand and the USA with capital raising and partnering negotiations. Dr. Campbell is also a Non-Executive Director of BioProspect Limited.

Patrys Limited, Annual General Meeting, Nov 12, 2014

Patrys Limited, Annual General Meeting, Nov 12, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PAB:AU A$0.01 AUD 0.00

PAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PAB.
View Industry Companies
 

Industry Analysis

PAB

Industry Average

Valuation PAB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PATRYS LTD, please visit www.patrys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.